Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2023. Start Trial.
Date Value
September 30, 2026 472.95M
June 30, 2026 409.54M
March 31, 2026 437.76M
December 31, 2025 369.22M
September 30, 2025 387.54M
June 30, 2025 219.24M
Date Value
March 31, 2025 235.42M
December 31, 2024 257.44M
September 30, 2024 271.37M
June 30, 2024 54.47M
March 31, 2024 69.31M
December 31, 2023 79.89M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Ligand Pharmaceuticals, Inc. 961.76M
Xeris Biopharma Holdings, Inc. 48.78M
ANI Pharmaceuticals, Inc. 637.11M
Corcept Therapeutics, Inc. 833.74M
Veru, Inc. 28.38M

Shareholders Equity (Quarterly) Related Metrics